Search Result

Results for "

Ikr

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Adrenergic Receptor (3) Autophagy (3) Calcium Channel (15) Cytochrome P450 (1) Indoleamine 2,3-Dioxygenase (IDO) (1) Isotope-Labeled Compounds (5) PKC (1) Potassium Channel (25) Reference Standards (6) Sodium Channel (13)
By Research Areas:	Cancer (9) Cardiovascular Disease (35) Metabolic Disease (4) Neurological Disease (3)

Inhibitors & Agonists

Peptides

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-B0772A

Nifekalant hydrochloride MS-551	Potassium Channel	Cardiovascular Disease
Nifekalant hydrochloride (MS-551), a class III antiarrhythmic agent, is a IKr potassium channel blocker with an IC₅₀ of 10 µM. Nifekalant hydrochloride can be used for refractory ventricular tachyarrhythmias research .

HY-101436A

Sematilide hydrochloride CK-1752 hydrochloride	Potassium Channel	Cardiovascular Disease
Sematilide hydrochloride (CK-1752 hydrochloride) is a selective *I_Kr* channel blocker. Sematilide causes a concentration-dependent inhibition of the delayed rectifier K ⁺ current (IC₅₀=25 μM). Sematilide is a class III antiarrhythmic agent .

HY-101327A

Xamoterol hemifumarate Corwin hemifumarate; ICI 118587 hemifumarate	Adrenergic Receptor	Cardiovascular Disease
Xamoterol hemifumarate is a selective and potent agonist of beta1-adrenergic receptor. Xamoterol hemifumarate has the potential for the research of arrhythmogenesis. Xamoterol hemifumarate has the potential for the investigating the relationship between β1-adrenergic stimulation and IKr .

HY-B0772

Nifekalant MS-551 free base	Potassium Channel	Cardiovascular Disease
Nifekalant (MS-551), a class III antiarrhythmic agent, is a IKr potassium channel blocker with an IC₅₀ of 10 μM. Nifekalant can be used for refractory ventricular tachyarrhythmias research .

HY-167866

Ersentilide	Adrenergic Receptor Potassium Channel	Cardiovascular Disease
Ersentilide, a benzamide derivative, is a is a β1-adrenoceptor antagonist and *Ikr* blocker. Ersentilide is effective in several intact animal models of arrhythmia .

HY-B0772AR

Nifekalant hydrochloride (Standard) MS-551 (Standard)	Reference Standards Potassium Channel	Cardiovascular Disease
Nifekalant (hydrochloride) (Standard) is the analytical standard of Nifekalant (hydrochloride). This product is intended for research and analytical applications. Nifekalant hydrochloride (MS-551), a class III antiarrhythmic agent, is a IKr potassium channel blocker with an IC₅₀ of 10 µM. Nifekalant hydrochloride can be used for refractory ventricular tachyarrhythmias research .

HY-101436

Sematilide CK-1752	Potassium Channel	Cardiovascular Disease
Sematilide (CK-1752) is a selective *I_Kr* channel blocker. Sematilide causes a concentration-dependent inhibition of the delayed rectifier K ⁺ current (IC₅₀=25 μM). Sematilide is a class III antiarrhythmic agent .

HY-101327

Xamoterol Corwin; ICI 118587	Adrenergic Receptor	Cardiovascular Disease
Xamoterol is a selective and potent agonist of beta1-adrenergic receptor. Xamoterol has the potential for the research of arrhythmogenesis. Xamoterol has the potential for the investigating the relationship between β1-adrenergic stimulation and IKr .

HY-101436AR

Sematilide hydrochloride (Standard) CK-1752 hydrochloride (Standard)	Reference Standards Potassium Channel	Cardiovascular Disease
Sematilide (hydrochloride) (Standard) is the analytical standard of Sematilide (hydrochloride). This product is intended for research and analytical applications. Sematilide hydrochloride (CK-1752 hydrochloride) is a selective IKr channel blocker. Sematilide causes a concentration-dependent inhibition of the delayed rectifier K+ current (IC50=25 μM). Sematilide is a class III antiarrhythmic agent .

HY-18600B

(E)-Azimilide (E)-NE-10064	Potassium Channel	Cardiovascular Disease
(E)-Azimilide is an isomer of Azimilide (HY-18600), a class of antiarrhythmic compounds that inhibit I(Ks) and I(Kr) activity .

HY-106855

Almokalant H 234/09	Potassium Channel	Cardiovascular Disease
Almokalant is a class III antiarrhythmic agent, acts as a potassium channel blocker, and inhibits a specific component (Ikr) of the time-dependent delayed rectifier K ⁺ current.

HY-B0232

Dofetilide Maximum Cited Publications 6 Publications Verification UK 68789	Potassium Channel	Cardiovascular Disease
Dofetilide (UK 68789), as a class III antiarrhythmic agent, is an orally active, potent and specific *IKr* blocker. Dofetilide can be used for the research of cardiovascular disease .

HY-B0387

Ibutilide fumarate 1 Publications Verification U70226E	Potassium Channel	Cardiovascular Disease
Ibutilide (U70226E) fumarate, an action potential-prolonging antiarrhythmic, is a potent blocker of the rapidly activating delayed rectifier K ⁺ current (I_Kr) in AT-1 cells .

HY-B0387A

Ibutilide 1 Publications Verification U70226E free base	Potassium Channel	Cardiovascular Disease
Ibutilide (U70226E free base), an action potential-prolonging antiarrhythmic, is a potent blocker of the rapidly activating delayed rectifier K ⁺ current (I_Kr) in AT-1 cells .

HY-P5881

PKCα (C2-4) inhibitor peptide	PKC	Cardiovascular Disease
PKCα (C2-4) inhibitor peptide is a PKCα specific inhibitor peptide that blocks the inhibition of I_Kr by the α_1A adrenoreceptor agonist A-61603 (HY-101366) .

HY-108163A

SB-237376	Calcium Channel Potassium Channel	Neurological Disease
SB-237376 is a blocker of potassium and calcium channels. SB-237376 inhibits the rapidly activating delayed rectifier potassium current I(Kr) (IC50: 0.42 μM) and blocks the L-type calcium current I(Ca,L) at high concentrations .

HY-B0232R

Dofetilide (Standard) UK 68789 (Standard)	Reference Standards Potassium Channel	Cardiovascular Disease
Dofetilide (Standard) is the analytical standard of Dofetilide. This product is intended for research and analytical applications. Dofetilide (UK 68789), as a class III antiarrhythmic agent, is an orally active, potent and specific *IKr* blocker. Dofetilide can be used for the research of cardiovascular disease .

HY-108163

SB-237376 free base	Calcium Channel Potassium Channel	Cardiovascular Disease
SB-237376 (free base) is a potassium and calcium channel blocker. SB-237376 (free base) can inhibit the rapidly activating delayed rectifier potassium current I(Kr) (IC₅₀ is 0.42 μM), and at high concentrations, it blocks the L-type calcium current I(Ca,L). In the rabbit ventricular model, SB-237376 (free base) can induce early afterdepolarizations (EADs) at a concentration of 3 µM. Compared to other IKr inhibitors such as dl-sotalol, SB-237376 has a lower proarrhythmic risk. SB-237376 (free base) holds potential for research in the field of arrhythmia-related diseases .

HY-B0387R

Ibutilide fumarate (Standard) U70226E (Standard)	Reference Standards Potassium Channel	Cardiovascular Disease
Ibutilide (fumarate) (Standard) is the analytical standard of Ibutilide (fumarate). This product is intended for research and analytical applications. Ibutilide (U70226E) fumarate, an action potential-prolonging antiarrhythmic, is a potent blocker of the rapidly activating delayed rectifier K ⁺ current (I_Kr) in AT-1 cells .

HY-17401

Ranolazine dihydrochloride 4 Publications Verification CVT 303 dihydrochloride; RS 43285	Calcium Channel Sodium Channel Autophagy	Cardiovascular Disease Cancer
Ranolazine dihydrochloride (CVT 303 dihydrochloride) is an anti-angina agent that achieves its effects by inhibiting the late phase of inward sodium current (I_Na and *I_Kr* with IC₅₀ values of 6 μM and 12 μM, respectively) without affecting heart rate or blood pressure (BP) . Ranolazine dihydrochloride is also a partial fatty acid oxidation inhibitor .

HY-108586

NS3623	Potassium Channel	Neurological Disease
NS3623 is an activator of human ether-a-go-go-related gene (hERG1/K_V11.1) potassium channels. NS3623 activates the *IKr* and Ito currents and has antiarrhythmic effect. NS3623 has a dual mode of action, being an inhibitor of hERG1 channels .

HY-B0280

Ranolazine 4 Publications Verification CVT 303; RS 43285-003	Sodium Channel Calcium Channel	Cardiovascular Disease Cancer
Ranolazine (CVT 303) is an anti-angina drug that achieves its effects by inhibiting the late phase of inward sodium current (I_Na and *I_Kr* with IC₅₀ values of 6 μM and 12 μM, respectively) without affecting heart rate or blood pressure (BP) . Ranolazine is also a partial fatty acid oxidation (FAO) inhibitor . Antianginal agent.

HY-17401S

Ranolazine-d8 dihydrochloride CVT 303-dd₈ dihydrochloride; RS 43285-d₈	Calcium Channel Sodium Channel Autophagy	Cardiovascular Disease Cancer
Ranolazine-d₈ (dihydrochloride) is the deuterium labeled Ranolazine dihydrochloride. Ranolazine dihydrochloride (CVT 303 dihydrochloride) is an anti-angina agent that achieves its effects by inhibiting the late phase of inward sodium current (INa and IKr with IC₅₀ values of 6 μM and 12 μM, respectively) without affecting heart rate or blood pressure (BP) . Ranolazine dihydrochloride is also a partial fatty acid oxidation inhibitor .

HY-17401R

Ranolazine dihydrochloride (Standard)	Calcium Channel Sodium Channel Autophagy	Cardiovascular Disease Cancer
Ranolazine (dihydrochloride) (Standard) is the analytical standard of Ranolazine (dihydrochloride). This product is intended for research and analytical applications. Ranolazine dihydrochloride (CVT 303 dihydrochloride) is an anti-angina agent that achieves its effects by inhibiting the late phase of inward sodium current (INa and IKr with IC50 values of 6 μM and 12 μM, respectively) without affecting heart rate or blood pressure (BP) . Ranolazine dihydrochloride is also a partial fatty acid oxidation inhibitor .

HY-B0280S2

Ranolazine-d3	Sodium Channel Calcium Channel	Cardiovascular Disease Cancer
Ranolazine-d₃ is the deuterium labeled Ranolazine. Ranolazine (CVT 303) is an anti-angina agent that achieves its effects by inhibiting the late phase of inward sodium current (INa and IKr with IC₅₀ values of 6 μM and 12 μM, respectively) without affecting heart rate or blood pressure (BP) . Ranolazine is also a partial fatty acid oxidation (FAO) inhibitor . Antianginal agent.

HY-B0280S

Ranolazine-d5 CVT 303-d₅; RS 43285-003-d₅	Isotope-Labeled Compounds Sodium Channel Calcium Channel	Cardiovascular Disease Cancer
Ranolazine-d₅ is the deuterium labeled Ranolazine. Ranolazine (CVT 303) is an anti-angina drug that achieves its effects by inhibiting the late phase of inward sodium current (INa and IKr with IC₅₀ values of 6 μM and 12 μM, respectively) without affecting heart rate or blood pressure (BP) . Ranolazine is also a partial fatty acid oxidation (FAO) inhibitor . Antianginal agent.

HY-B0280S1

Ranolazine-d8	Isotope-Labeled Compounds Sodium Channel Calcium Channel	Cardiovascular Disease Cancer
Ranolazine-d₈ is the deuterium labeled Ranolazine. Ranolazine (CVT 303) is an anti-angina agent that achieves its effects by inhibiting the late phase of inward sodium current (INa and IKr with IC₅₀ values of 6 μM and 12 μM, respectively) without affecting heart rate or blood pressure (BP) . Ranolazine is also a partial fatty acid oxidation (FAO) inhibitor . Antianginal agent.

HY-B0280R

Ranolazine (Standard) CVT 303 (Standard); RS 43285-003 (Standard)	Reference Standards Sodium Channel Calcium Channel	Cardiovascular Disease Cancer
Ranolazine (Standard) is the analytical standard of Ranolazine. This product is intended for research and analytical applications. Ranolazine (CVT 303) is an anti-angina drug that achieves its effects by inhibiting the late phase of inward sodium current (I_Na and *I_Kr* with IC₅₀ values of 6 μM and 12 μM, respectively) without affecting heart rate or blood pressure (BP) . Ranolazine is also a partial fatty acid oxidation (FAO) inhibitor . Antianginal agent.

HY-106577

Cibenzoline Cifenline; Ro 22-7796	Potassium Channel	Cardiovascular Disease Metabolic Disease
Cibenzoline is a class Ia antiarrhythmic active molecule with low anticholinergic activity. Cibenzoline is a K_ATP channel inhibitor, acting through the pore forming subunit Kir6.2, with an IC₅₀ of 22.2 μM. Cibenzoline inhibits I_Kr and I_Ks currents with IC₅₀ values of 8.8 μM and 12.3 μM, respectively. Cibenzoline is used in the study of cardiac diseases. In addition, Cibenzoline can induce hypoglycemia .

HY-144652

IDO1-IN-19	Indoleamine 2,3-Dioxygenase (IDO) Calcium Channel Sodium Channel Potassium Channel Cytochrome P450	Cardiovascular Disease Cancer
IDO1-IN-19 (Compound 17) is an orally active IDO1 inhibitor with an IC₅₀ of CYP2C9 of 8.64 μM. IDO1-IN-19 also acts funciton on cardiac channels, with IC₅₀s of 12 μM (IKr), 40 μM (INa), 8.3 μM (ICa), respectively. IDO1-IN-19 has the potential to study cancer diseases .

HY-106577R

Cibenzoline (Standard) Cifenline (Standard); Ro 22-7796 (Standard)	Reference Standards Potassium Channel	Cardiovascular Disease Metabolic Disease
Cibenzoline (Standard) is the analytical standard of Cibenzoline. This product is intended for research and analytical applications. Cibenzoline is a class Ia antiarrhythmic active molecule with low anticholinergic activity. Cibenzoline is a K_ATP channel inhibitor, acting through the pore forming subunit Kir6.2, with an IC₅₀ of 22.2 μM. Cibenzoline inhibits I_Kr and I_Ks currents with IC₅₀ values of 8.8 μM and 12.3 μM, respectively. Cibenzoline is used in the study of cardiac diseases. In addition, Cibenzoline can induce hypoglycemia .

HY-106577S

Cibenzoline-d4 Cifenline-d₄; Ro 22-7796-d₄	Isotope-Labeled Compounds Potassium Channel	Cardiovascular Disease Metabolic Disease
Cibenzoline-d₄ (Cifenline-d₄) is deuterium labeled Cibenzoline. Cibenzoline is a class Ia antiarrhythmic active molecule with low anticholinergic activity. Cibenzoline is a K_ATP channel inhibitor, acting through the pore forming subunit Kir6.2, with an IC₅₀ of 22.2 μM. Cibenzoline inhibits I_Kr and I_Ks currents with IC₅₀ values of 8.8 μM and 12.3 μM, respectively. Cibenzoline is used in the study of cardiac diseases. In addition, Cibenzoline can induce hypoglycemia .

HY-106577S1

Cibenzoline-d5 Cifenline-d₅; Ro 22-7796-d₅	Isotope-Labeled Compounds	Cardiovascular Disease Metabolic Disease
Cibenzoline-d₅ (Cifenline-d₅) is deuterium labeled Cibenzoline. Cibenzoline is a class Ia antiarrhythmic active molecule with low anticholinergic activity. Cibenzoline is a K_ATP channel inhibitor, acting through the pore forming subunit Kir6.2, with an IC₅₀ of 22.2 μM. Cibenzoline inhibits I_Kr and I_Ks currents with IC₅₀ values of 8.8 μM and 12.3 μM, respectively. Cibenzoline is used in the study of cardiac diseases. In addition, Cibenzoline can induce hypoglycemia .

HY-18600A

Azimilide dihydrochloride 2 Publications Verification NE-10064 dihydrochloride	Potassium Channel Calcium Channel Sodium Channel	Cardiovascular Disease
Azimilide (NE-10064) dihydrochloride is a class III antiarrhythmic agent, which works by blocking potassium channels in the heart. Azimilide dihydrochloride is a dual blocker of I_Ks (IC₅₀ = 2.6 μM (2mM [K⁺]ₑ)) and *I_Kr* (IC₅₀ = 1 μM (4 mM [K⁺])). Azimilide dihydrochloride blocked HERG channel at 0.1 and 1 Hz with IC₅₀s of 1.4 μM and 5.2 μM respectively. Azimilide dihydrochloride also inhibits L-type calcium current (I_Ca) (IC₅₀ = 17.8 μM) and sodium current (I_Na) (IC₅₀ = 19 μM). Azimilide dihydrochloride can be used for the study of atrial fibrillation and ventricular fibrillation .

HY-18600

Azimilide 2 Publications Verification NE-10064	Potassium Channel Calcium Channel Sodium Channel	Cardiovascular Disease
Azimilide (NE-10064) is a class III antiarrhythmic agent, which works by blocking potassium channels in the heart. Azimilide is a dual blocker of I_Ks (IC₅₀ = 2.6 μM (2mM [K⁺]ₑ)) and *I_Kr* (IC₅₀ = 1 μM (4 mM [K⁺])). Azimilide blocked HERG channel at 0.1 and 1 Hz with IC₅₀s of 1.4 μM and 5.2 μM respectively. Azimilide also inhibits L-type calcium current (I_Ca) (IC₅₀ = 17.8 μM) and sodium current (I_Na) (IC₅₀ = 19 μM). Azimilide can be used for the study of atrial fibrillation and ventricular fibrillation .

HY-111245

AZD-1305	Potassium Channel Calcium Channel Sodium Channel	Cardiovascular Disease Neurological Disease
AZD-1305 is an antiarrhythmic agent and atrial selective sodium channel/potassium channel blocker, which can significantly prolongs action potential duration and reduces excitability, cause atrial selective ERP prolongation and acute termination of atrial fibrillation. AZD1305 can be used for atrial fibrillation research .

HY-18600AS

Azimilide-d8 dihydrochloride NE-10064-dd₈ dihydrochloride	Isotope-Labeled Compounds Potassium Channel Calcium Channel Sodium Channel	Cardiovascular Disease
Azimilide-d₈ (NE-10064-d₈) dihydrochloride is the deuterium labeled Azimilide dihydrochloride (HY-18600A). Azimilide dihydrochloride is a class III antiarrhythmic agent, which works by blocking potassium channels in the heart. Azimilide dihydrochloride is a dual blocker of I_Ks (IC₅₀ = 2.6 μM (2mM [K⁺]ₑ)) and *I_Kr* (IC₅₀ = 1 μM (4 mM [K⁺])). Azimilide dihydrochloride blocked HERG channel at 0.1 and 1 Hz with IC₅₀s of 1.4 μM and 5.2 μM respectively. Azimilide dihydrochloride also inhibits L-type calcium current (I_Ca) (IC₅₀ = 17.8 μM) and sodium current (I_Na) (IC₅₀ = 19 μM). Azimilide dihydrochloride can be used for the study of atrial fibrillation and ventricular fibrillation .

Cat. No.	Product Name	Target	Research Area

HY-P5881

PKCα (C2-4) inhibitor peptide	PKC	Cardiovascular Disease
PKCα (C2-4) inhibitor peptide is a PKCα specific inhibitor peptide that blocks the inhibition of I_Kr by the α_1A adrenoreceptor agonist A-61603 (HY-101366) .

Cat. No.	Product Name	Chemical Structure

HY-17401S

Ranolazine-d8 dihydrochloride
Ranolazine-d₈ (dihydrochloride) is the deuterium labeled Ranolazine dihydrochloride. Ranolazine dihydrochloride (CVT 303 dihydrochloride) is an anti-angina agent that achieves its effects by inhibiting the late phase of inward sodium current (INa and IKr with IC₅₀ values of 6 μM and 12 μM, respectively) without affecting heart rate or blood pressure (BP) . Ranolazine dihydrochloride is also a partial fatty acid oxidation inhibitor .

Ranolazine-d8 dihydrochloride

Ranolazine-d₈ (dihydrochloride) is the deuterium labeled Ranolazine dihydrochloride. Ranolazine dihydrochloride (CVT 303 dihydrochloride) is an anti-angina agent that achieves its effects by inhibiting the late phase of inward sodium current (INa and IKr with IC₅₀ values of 6 μM and 12 μM, respectively) without affecting heart rate or blood pressure (BP) . Ranolazine dihydrochloride is also a partial fatty acid oxidation inhibitor .

HY-B0280S2

Ranolazine-d3
Ranolazine-d₃ is the deuterium labeled Ranolazine. Ranolazine (CVT 303) is an anti-angina agent that achieves its effects by inhibiting the late phase of inward sodium current (INa and IKr with IC₅₀ values of 6 μM and 12 μM, respectively) without affecting heart rate or blood pressure (BP) . Ranolazine is also a partial fatty acid oxidation (FAO) inhibitor . Antianginal agent.

HY-B0280S1

Ranolazine-d8
Ranolazine-d₈ is the deuterium labeled Ranolazine. Ranolazine (CVT 303) is an anti-angina agent that achieves its effects by inhibiting the late phase of inward sodium current (INa and IKr with IC₅₀ values of 6 μM and 12 μM, respectively) without affecting heart rate or blood pressure (BP) . Ranolazine is also a partial fatty acid oxidation (FAO) inhibitor . Antianginal agent.

HY-B0280S

Ranolazine-d5
Ranolazine-d₅ is the deuterium labeled Ranolazine. Ranolazine (CVT 303) is an anti-angina drug that achieves its effects by inhibiting the late phase of inward sodium current (INa and IKr with IC₅₀ values of 6 μM and 12 μM, respectively) without affecting heart rate or blood pressure (BP) . Ranolazine is also a partial fatty acid oxidation (FAO) inhibitor . Antianginal agent.

HY-106577S

Cibenzoline-d4
Cibenzoline-d₄ (Cifenline-d₄) is deuterium labeled Cibenzoline. Cibenzoline is a class Ia antiarrhythmic active molecule with low anticholinergic activity. Cibenzoline is a K_ATP channel inhibitor, acting through the pore forming subunit Kir6.2, with an IC₅₀ of 22.2 μM. Cibenzoline inhibits I_Kr and I_Ks currents with IC₅₀ values of 8.8 μM and 12.3 μM, respectively. Cibenzoline is used in the study of cardiac diseases. In addition, Cibenzoline can induce hypoglycemia .

Cibenzoline-d4

Cibenzoline-d₄ (Cifenline-d₄) is deuterium labeled Cibenzoline. Cibenzoline is a class Ia antiarrhythmic active molecule with low anticholinergic activity. Cibenzoline is a K_ATP channel inhibitor, acting through the pore forming subunit Kir6.2, with an IC₅₀ of 22.2 μM. Cibenzoline inhibits I_Kr and I_Ks currents with IC₅₀ values of 8.8 μM and 12.3 μM, respectively. Cibenzoline is used in the study of cardiac diseases. In addition, Cibenzoline can induce hypoglycemia .

HY-106577S1

Cibenzoline-d5
Cibenzoline-d₅ (Cifenline-d₅) is deuterium labeled Cibenzoline. Cibenzoline is a class Ia antiarrhythmic active molecule with low anticholinergic activity. Cibenzoline is a K_ATP channel inhibitor, acting through the pore forming subunit Kir6.2, with an IC₅₀ of 22.2 μM. Cibenzoline inhibits I_Kr and I_Ks currents with IC₅₀ values of 8.8 μM and 12.3 μM, respectively. Cibenzoline is used in the study of cardiac diseases. In addition, Cibenzoline can induce hypoglycemia .

Cibenzoline-d5

Cibenzoline-d₅ (Cifenline-d₅) is deuterium labeled Cibenzoline. Cibenzoline is a class Ia antiarrhythmic active molecule with low anticholinergic activity. Cibenzoline is a K_ATP channel inhibitor, acting through the pore forming subunit Kir6.2, with an IC₅₀ of 22.2 μM. Cibenzoline inhibits I_Kr and I_Ks currents with IC₅₀ values of 8.8 μM and 12.3 μM, respectively. Cibenzoline is used in the study of cardiac diseases. In addition, Cibenzoline can induce hypoglycemia .

HY-18600AS

Azimilide-d8 dihydrochloride

Azimilide-d₈ (NE-10064-d₈) dihydrochloride is the deuterium labeled Azimilide dihydrochloride (HY-18600A). Azimilide dihydrochloride is a class III antiarrhythmic agent, which works by blocking potassium channels in the heart. Azimilide dihydrochloride is a dual blocker of I_Ks (IC₅₀ = 2.6 μM (2mM [K⁺]ₑ)) and I_Kr (IC₅₀ = 1 μM (4 mM [K⁺])). Azimilide dihydrochloride blocked HERG channel at 0.1 and 1 Hz with IC₅₀s of 1.4 μM and 5.2 μM respectively. Azimilide dihydrochloride also inhibits L-type calcium current (I_Ca) (IC₅₀ = 17.8 μM) and sodium current (I_Na) (IC₅₀ = 19 μM). Azimilide dihydrochloride can be used for the study of atrial fibrillation and ventricular fibrillation .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: